Similar articles

• [Arteriosclerosis with special reference to anticholesteremic agents].

  Murakami M, Sekimoto H, Nakada I, Takegoshi T, Iwaki N. Murakami M, et al. Naika. 1970 Jun;25(6):1082-6. Naika. 1970. PMID: 5431239 Japanese. No abstract available.
• [Clinical evaluation of the therapeutic activity of the -pyridyl-carbinol ester of clofibric acid].

  Silingardi V, Renzi R, Mora A, Di Prisco AU. Silingardi V, et al. Minerva Med. 1973 Mar 21;64(16):751-69. Minerva Med. 1973. PMID: 4704721 Italian. No abstract available.
• [Clinical experience with an antilipemic agent, ethylchlorophenoxyisobutyrate].

  Noleto PA, de Bulhões F, Tuma M. Noleto PA, et al. Rev Bras Med. 1969 Oct;26(10):602-5. Rev Bras Med. 1969. PMID: 5404870 Portuguese. No abstract available.
• [Morphochemical and biochemical principles of atherosclerosis pharmacotherapy].

  Godlewski HG. Godlewski HG. Postepy Hig Med Dosw. 1977 May-Jun;31(2):171-230. Postepy Hig Med Dosw. 1977. PMID: 329244 Review. Polish. No abstract available.
• [Currently used therapeutic agents for arteriosclerosis--with special reference to a protein anabolic hormone, clofibrate (C.P.I.B.)].

  Yasugi T, Sasa E. Yasugi T, et al. Nihon Rinsho. 1970 May;28(5):1470-4. Nihon Rinsho. 1970. PMID: 4915308 Review. Japanese. No abstract available.